AMPLATZER PFO OCCLUDER

Transcatheter Septal Occluder

FDA Premarket Approval P120021

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the amplatzer pfo occluder. The device is indicated for percutaneous transcatheter closure of a patent foramen ovale (pfo) to reduce the risk of recurrent ischemic stroke in patients, predominantly between the ages of 18 and 60 years, who have had a cryptogenic stroke due to a presumed paradoxical embolism, as determined by a neurologist and cardiologist following an evaluation to exclude known causes of ischemic stroke.

DeviceAMPLATZER PFO OCCLUDER
Classification NameTranscatheter Septal Occluder
Generic NameTranscatheter Septal Occluder
ApplicantAbbott Medical
Date Received2012-11-30
Decision Date2016-10-28
Notice Date2016-11-01
PMAP120021
SupplementS
Product CodeMLV
Docket Number16M-3653
Advisory CommitteeCardiovascular
Expedited ReviewNo
Combination Product No
Applicant Address Abbott Medical 5050 Nathan Lane North plymouth, MN 55442
Summary:Summary of Safety and Effectiveness
Labeling: Labeling Labeling Part 2
Post-Approval Study:Show Report Schedule and Study Progress
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P120021Original Filing
S023 2021-11-26 Normal 180 Day Track No User Fee
S022
S021 2021-06-28 30-day Notice
S020
S019
S018 2020-05-06 30-day Notice
S017 2020-04-24 30-day Notice
S016
S015 2020-03-19 30-day Notice
S014 2020-03-17 30-day Notice
S013 2019-09-26 30-day Notice
S012 2019-06-24 Normal 180 Day Track No User Fee
S011 2019-02-27 30-day Notice
S010 2019-02-15 Normal 180 Day Track No User Fee
S009 2019-01-03 30-day Notice
S008
S007 2018-02-12 30-day Notice
S006 2018-01-30 Real-time Process
S005
S004 2017-07-06 30-day Notice
S003 2017-01-26 30-day Notice
S002 2016-11-23 Normal 180 Day Track No User Fee
S001 2016-11-17 Normal 180 Day Track No User Fee

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.